Cargando…

BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study

BACKGROUND: Insertable cardiac monitors are utilized for the diagnosis of arrhythmias and traditionally have been inserted within hospitals. Recent code updates allow for reimbursement of office-based insertions; however, there is limited information regarding the resources and processes required to...

Descripción completa

Detalles Bibliográficos
Autores principales: Awad, Khaled, Weiss, Raul, Yunus, Asim, Bittrick, Jon M., Nekkanti, Rajasekhar, Houmsse, Mahmoud, Okabe, Toshimasa, Adamson, Teagan, Miller, Crystal, Alawwa, Abdul K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161128/
https://www.ncbi.nlm.nih.gov/pubmed/32293279
http://dx.doi.org/10.1186/s12872-020-01439-8
_version_ 1783522895499100160
author Awad, Khaled
Weiss, Raul
Yunus, Asim
Bittrick, Jon M.
Nekkanti, Rajasekhar
Houmsse, Mahmoud
Okabe, Toshimasa
Adamson, Teagan
Miller, Crystal
Alawwa, Abdul K.
author_facet Awad, Khaled
Weiss, Raul
Yunus, Asim
Bittrick, Jon M.
Nekkanti, Rajasekhar
Houmsse, Mahmoud
Okabe, Toshimasa
Adamson, Teagan
Miller, Crystal
Alawwa, Abdul K.
author_sort Awad, Khaled
collection PubMed
description BACKGROUND: Insertable cardiac monitors are utilized for the diagnosis of arrhythmias and traditionally have been inserted within hospitals. Recent code updates allow for reimbursement of office-based insertions; however, there is limited information regarding the resources and processes required to support in-office insertions. We sought to determine the safety and feasibility of in-office insertion of the BioMonitor 2 and better understand in-office procedures, including patient selection, pre-insertion protocols, resource availability, and staff support. METHODS: Patients meeting an indication for a rhythm monitor were prospectively enrolled into this single-arm, non-randomized trial. All patients underwent insertion in an office setting. Two follow-up visits at days 7 and 90 were required. Information on adverse events, device performance, office site preparations, and resource utilization were collected. RESULTS: Eighty-two patients were enrolled at six sites. Insertion was successful in all 77 patients with an attempt. Oral anticoagulation was stopped in 20.8% of patients and continued through insertion in 23.4%, while prophylactic antibiotics were infrequently utilized (37.7% of study participants). On average, the procedure required a surgeon plus two support staff and 35 min in an office room to complete the 8.4 min insertion procedure. The mean R-wave amplitude was 0.77 mV at insertion and 0.67 mV at 90-days with low noise burden (2.7%). There were no procedure related complications. Two adverse events were reported (event rate 2.7% [95% CI 0.3, 9.5%]). CONCLUSIONS: In-office insertion of the BioMonitor 2 is safe and feasible. Devices performed well with high R-wave amplitudes and low noise burden. These results further support shifting cardiac monitor insertions to office-based locations. TRIAL REGISTRATION: clinicaltrials.gov, NCT02756338. Registered 29 April 2016.
format Online
Article
Text
id pubmed-7161128
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71611282020-04-22 BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study Awad, Khaled Weiss, Raul Yunus, Asim Bittrick, Jon M. Nekkanti, Rajasekhar Houmsse, Mahmoud Okabe, Toshimasa Adamson, Teagan Miller, Crystal Alawwa, Abdul K. BMC Cardiovasc Disord Research Article BACKGROUND: Insertable cardiac monitors are utilized for the diagnosis of arrhythmias and traditionally have been inserted within hospitals. Recent code updates allow for reimbursement of office-based insertions; however, there is limited information regarding the resources and processes required to support in-office insertions. We sought to determine the safety and feasibility of in-office insertion of the BioMonitor 2 and better understand in-office procedures, including patient selection, pre-insertion protocols, resource availability, and staff support. METHODS: Patients meeting an indication for a rhythm monitor were prospectively enrolled into this single-arm, non-randomized trial. All patients underwent insertion in an office setting. Two follow-up visits at days 7 and 90 were required. Information on adverse events, device performance, office site preparations, and resource utilization were collected. RESULTS: Eighty-two patients were enrolled at six sites. Insertion was successful in all 77 patients with an attempt. Oral anticoagulation was stopped in 20.8% of patients and continued through insertion in 23.4%, while prophylactic antibiotics were infrequently utilized (37.7% of study participants). On average, the procedure required a surgeon plus two support staff and 35 min in an office room to complete the 8.4 min insertion procedure. The mean R-wave amplitude was 0.77 mV at insertion and 0.67 mV at 90-days with low noise burden (2.7%). There were no procedure related complications. Two adverse events were reported (event rate 2.7% [95% CI 0.3, 9.5%]). CONCLUSIONS: In-office insertion of the BioMonitor 2 is safe and feasible. Devices performed well with high R-wave amplitudes and low noise burden. These results further support shifting cardiac monitor insertions to office-based locations. TRIAL REGISTRATION: clinicaltrials.gov, NCT02756338. Registered 29 April 2016. BioMed Central 2020-04-15 /pmc/articles/PMC7161128/ /pubmed/32293279 http://dx.doi.org/10.1186/s12872-020-01439-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Awad, Khaled
Weiss, Raul
Yunus, Asim
Bittrick, Jon M.
Nekkanti, Rajasekhar
Houmsse, Mahmoud
Okabe, Toshimasa
Adamson, Teagan
Miller, Crystal
Alawwa, Abdul K.
BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study
title BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study
title_full BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study
title_fullStr BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study
title_full_unstemmed BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study
title_short BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study
title_sort biomonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort bioinsight study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161128/
https://www.ncbi.nlm.nih.gov/pubmed/32293279
http://dx.doi.org/10.1186/s12872-020-01439-8
work_keys_str_mv AT awadkhaled biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy
AT weissraul biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy
AT yunusasim biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy
AT bittrickjonm biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy
AT nekkantirajasekhar biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy
AT houmssemahmoud biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy
AT okabetoshimasa biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy
AT adamsonteagan biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy
AT millercrystal biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy
AT alawwaabdulk biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy